We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Optimized Tests for Highly Reliable Diagnosis of Zika

By LabMedica International staff writers
Posted on 24 May 2016
Upon finding that several conventional Zika virus tests are not sufficiently reliable, scientists have developed and made available optimized assays as well as a control for quantifying Zika virus RNA in patient samples (blood and urine).

Diagnosing viruses reliably is of major importance for individual patients and for monitoring and research on virus spread in populations. More...
Currently, acute Zika infections are predominantly confirmed by genetic analysis. Six tests developed prior to the outbreak are currently being used. However there has been concern that numerous Zika infections are going undetected: can they detect viral RNA at very low concentrations? Are they sensitive enough to identify Zika virus strains? Are their results comparable to each other?

A scientific team from the German Center for Infection Research (DZIF; Braunschweig, Germany) and the University of Bonn (Bonn, Germany), led by Prof Felix Drexler and Prof Christian Drosten, has now carefully examined the existing tests and developed optimized assays. The team previously developed the globally used, standardized test for the MERS pathogen.

All currently used PCR assays test for Zika virus RNA; they differ especially in examining different regions. PCR tests are suitable for early virus detection in the first weeks after onset of symptoms, whereas serological tests for patient antibodies to Zika virus are recommended for use after the 8th day.

Toward minimizing diagnostic uncertainties, the team initially compared the commonly used PCR tests for sensitivity. The comparison confirmed the concerns: that some of the tests were not sensitive enough to detect low concentrations of viruses. Additionally, not all virus strains are detected uniformly across the testing systems. Comparability between the assays is limited. The researchers assume that, depending on the system, 20-80% of patients may be incorrectly diagnosed, if serological testing methods are not used for further analysis.

The team consequently developed two optimized PCR tests, as well as a “calibrator” control that not only validates each test but also quantifies the viral RNA in the sample. The calibrator is synthetically constructed RNA that contains all the different viral RNA target zones used in the different conventional PCR tests.

"With our study, we especially wanted to call attention to the fact that a negative PCR test is not necessarily reliable," explained Prof. Drexler. The researchers have already made their results freely available prior to publication on the World Health Organization (WHO) server. The test protocols and calibrator can be ordered free of charge. The project was supported by DZIF and the European Union. In such outbreak situations, all parties involved should exchange data as early as possible and have access to the best diagnostic tools available.

The study, by Corman VM et al, was published online April 19, 2016, in the Bulletin of the World Health Organization.

Related Links:
German Center for Infection Research
University of Bonn

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.